Uro Medical

Uro Medical is a private medical-device company focused on urology, with a stated emphasis on developing, manufacturing, and commercializing micro-sized neurostimulators. Its Protect PNS System targets overactive bladder through tibial nerve stimulation, a focused indication and treatment approach rather than a broad portfolio of disclosed product areas. GUARDIAN and PROTECT are identified as clinical trials for patients who have not responded to pharmaceutical treatment, while a 2022 announcement described CMS coverage for a second trial. Its position is best characterized as a focused clinical-stage neurostimulation effort in urology, not a demonstrated market leader.

Uro Medical’s visible development path runs from its 2019 founding to clinical evaluation of a micro-neurostimulation treatment for overactive bladder. A Jun 30, 2022 announcement that CMS coverage had been secured for a second clinical trial marked a further step in trial access for its wireless microstimulator program. GUARDIAN and PROTECT are both described as investigational-device trials for patients who have not responded to drug therapy. The company’s current product narrative centers on the Protect PNS System and tibial nerve stimulation; no launch date, FDA clearance, or commercial sales milestone is provided. With no disclosed funding rounds or valuation, the pace and resources behind the next development stage remain unclear.